Fig. 1: CREB3L2 is upregulated and associates with poor outcomes in HCC. | Cell Death & Disease

Fig. 1: CREB3L2 is upregulated and associates with poor outcomes in HCC.

From: Targeting CREB3L2-mediated lipid metabolism overcomes lenvatinib resistance and attenuates the progression of hepatocellular carcinoma

Fig. 1

A Relative expression profiles of CREB3L2 across multiple tumor types with liver hepatocellular carcinoma (LIHC), cholangiocarcinoma (CHOL), lung adenocarcinomastomach (LUAD), colon adenocarcinoma (COAD), rectum adenocarcinoma(READ), and glioblastoma multiformebased (GBM) on the TCGA database. B The expression profiles of CREB3L2 within three patient-specific datasets of HCC sourced from the GEO database (sample identifiers GSE102079, GSE14520, and GSE22405). C Survival prognosis curves of HCC patients with different CREB3L2 expression levels. D The relative expression levels of CREB3L2 mRNA within 30 pairs of HCC tissues and their adjacent non-neoplastic counterparts. E The expression profile of CREB3L2 protein in 10 pairs of liver cancer tissues and their paired adjacent tissues. F Typical immunohistochemical staining images illustrate the distinctions in CREB3L2 expression levels between hepatocellular carcinoma (HCC) tissues and their peritumoral counterparts. G IHC staining scores for the expression of CREB3L2 protein in 176 sets of paired tumor tissues. H, I Prognostic curves showing OS and RFS of patients in Cohort 2. J Multivariate Cox analysis of OS clinical prognostic parameters. *P < 0.05; **P < 0.01; ***P < 0.001.

Back to article page